Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Current Assets: 2011-2025

Historic Current Assets for Abeona Therapeutics (ABEO) over the last 15 years, with Sep 2025 value amounting to $216.1 million.

  • Abeona Therapeutics' Current Assets rose 91.85% to $216.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.1 million, marking a year-over-year increase of 91.85%. This contributed to the annual value of $100.9 million for FY2024, which is 80.94% up from last year.
  • According to the latest figures from Q3 2025, Abeona Therapeutics' Current Assets is $216.1 million, which was down 6.95% from $232.3 million recorded in Q2 2025.
  • Abeona Therapeutics' Current Assets' 5-year high stood at $232.3 million during Q2 2025, with a 5-year trough of $25.5 million in Q3 2022.
  • Over the past 3 years, Abeona Therapeutics' median Current Assets value was $88.1 million (recorded in 2025), while the average stood at $103.9 million.
  • Its Current Assets has fluctuated over the past 5 years, first crashed by 62.45% in 2022, then soared by 185.90% in 2024.
  • Over the past 5 years, Abeona Therapeutics' Current Assets (Quarterly) stood at $56.3 million in 2021, then dropped by 5.67% to $53.1 million in 2022, then climbed by 4.97% to $55.7 million in 2023, then spiked by 80.94% to $100.9 million in 2024, then skyrocketed by 91.85% to $216.1 million in 2025.
  • Its Current Assets stands at $216.1 million for Q3 2025, versus $232.3 million for Q2 2025 and $88.1 million for Q1 2025.